Sichuan Goldstone Asia Pharmaceutical Past Earnings Performance
Past criteria checks 1/6
Sichuan Goldstone Asia Pharmaceutical has been growing earnings at an average annual rate of 17.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 7.5% per year. Sichuan Goldstone Asia Pharmaceutical's return on equity is 2.7%, and it has net margins of 6.3%.
Key information
17.9%
Earnings growth rate
17.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 7.5% |
| Return on equity | 2.7% |
| Net Margin | 6.3% |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses BreakdownBeta
How Sichuan Goldstone Asia Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,152 | 73 | 441 | 41 |
| 31 Dec 23 | 1,209 | 126 | 430 | 50 |
| 30 Sep 23 | 1,358 | 251 | 437 | 49 |
| 30 Jun 23 | 1,397 | 292 | 434 | 45 |
| 31 Mar 23 | 1,347 | 296 | 412 | 44 |
| 31 Dec 22 | 1,243 | 219 | 423 | 39 |
| 30 Sep 22 | 1,033 | 93 | 418 | 40 |
| 30 Jun 22 | 997 | 75 | 403 | 29 |
| 31 Mar 22 | 992 | 54 | 391 | 29 |
| 01 Jan 22 | 1,054 | 66 | 423 | 37 |
| 30 Sep 21 | 1,025 | -512 | 395 | 38 |
| 30 Jun 21 | 976 | -617 | 403 | 46 |
| 31 Mar 21 | 946 | -628 | 413 | 43 |
| 31 Dec 20 | 777 | -688 | 380 | 28 |
| 30 Sep 20 | 880 | -42 | 420 | 29 |
| 30 Jun 20 | 923 | 73 | 418 | 28 |
| 31 Mar 20 | 935 | 89 | 416 | 30 |
| 31 Dec 19 | 1,006 | 120 | 431 | 29 |
| 30 Sep 19 | 970 | 150 | 404 | 29 |
| 30 Jun 19 | 962 | 150 | 396 | 28 |
| 31 Mar 19 | 989 | 153 | 405 | 29 |
| 31 Dec 18 | 971 | 149 | 410 | 28 |
| 30 Sep 18 | 994 | 151 | 418 | 27 |
| 30 Jun 18 | 989 | 152 | 397 | 33 |
| 31 Mar 18 | 934 | 170 | 355 | 25 |
| 31 Dec 17 | 704 | 116 | 256 | 21 |
| 30 Sep 17 | 369 | 41 | 117 | 11 |
| 30 Jun 17 | 228 | 27 | 69 | 0 |
| 31 Mar 17 | 166 | 17 | 44 | 0 |
| 31 Dec 16 | 162 | 26 | 34 | 0 |
| 30 Sep 16 | 135 | 20 | 30 | 0 |
| 30 Jun 16 | 125 | 20 | 27 | 0 |
| 31 Mar 16 | 104 | 17 | 26 | 0 |
| 31 Dec 15 | 117 | 23 | 27 | 0 |
| 30 Sep 15 | 125 | 23 | 29 | 0 |
| 30 Jun 15 | 142 | 28 | 28 | 0 |
| 31 Mar 15 | 162 | 32 | 27 | 0 |
| 31 Dec 14 | 173 | 32 | 30 | 0 |
| 31 Dec 13 | 239 | 49 | 32 | 0 |
Quality Earnings: 300434 has a large one-off loss of CN¥86.5M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 300434's current net profit margins (6.3%) are lower than last year (21.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300434's earnings have grown by 17.9% per year over the past 5 years.
Accelerating Growth: 300434's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300434 had negative earnings growth (-75.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.5%).
Return on Equity
High ROE: 300434's Return on Equity (2.7%) is considered low.